HomeIndustriesHealthcareLLY, MRK, PFE: Biopharma’s Back In 2024

LLY, MRK, PFE: Biopharma’s Back In 2024

Expect 2024 to be the year of gradual recovery for biopharmaceuticals, notes CFRA’s Sel Hardy. She and Jefferies’ Brian Tanquilut discuss health care trends to watch in 2024. Hardy mentions that oncology and diabetes will be the fastest growing therapy areas. Her top stock picks include Eli Lilly (LLY), Merck (MRK), and Pfizer (PFE). Tanquilut highlights that Jefferies continues to like HCA given the solid company fundamentals, reasonable valuation, and opportunity for earnings upside. Tune in to find out more about the stock market today.

Trading 360

13 Dec 2023

SHARE

ON AIR
education
6:00 am
Schwab 2026 Outlook
replay
education
12:00 am
Schwab 2026 Outlook
REPLAY
1:00 am
Market Overtime
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Market Overtime
REPLAY
4:30 am
Market Overtime
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
Market Overtime
REPLAY
ON AIR
education
6:00 am
Schwab 2026 Outlook
REPLAY
7:00 am
Market Overtime
REPLAY
education
8:00 am
Your First Trade
REPLAY
education
8:30 am
Your First Trade
REPLAY
9:00 am
Fast Market
REPLAY
10:00 am
Market Overtime
REPLAY
10:30 am
Market Overtime
REPLAY
11:00 am
Market Overtime
REPLAY
11:30 am
Market Overtime
REPLAY
education
12:00 pm
Schwab 2026 Outlook
REPLAY
1:00 pm
Market Overtime
REPLAY
education
2:00 pm
Your First Trade
REPLAY
education
2:30 pm
Your First Trade
REPLAY
3:00 pm
Fast Market
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market Overtime
REPLAY
5:00 pm
Market Overtime
REPLAY
5:30 pm
Market Overtime
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Market Overtime
REPLAY
education
8:00 pm
Your First Trade
REPLAY
education
8:30 pm
Your First Trade
REPLAY
9:00 pm
Fast Market
REPLAY
10:00 pm
Market Overtime
REPLAY
10:30 pm
Market Overtime
REPLAY
11:00 pm
Market Overtime
REPLAY
11:30 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor